comparemela.com

Bristol Myers Squibb & Co (NYSE: BMY) said that its Q2 revenues of $11.23 billion declined 6% Y/Y, or 5% when adjusted for foreign exchange, due to lower sales of Revlimid, partially offset by in-line products and our new product portfolio.

Related Keywords

Canada ,Bristol Myers ,Bristol Myers Squibb Co ,Bristol Myers Squibb ,Patient Assistance Foundation ,Patient Assistance ,

© 2024 Vimarsana

comparemela.com © 2020. All Rights Reserved.